Home › RegulatoryAldeyra Therapeutics, Inc. - 10-Q FilingAldeyra Therapeutics reports Q3 2026 net loss of $3.76M and cash reserves of $41.0M.SEC EDGAR · November 5, 2026, 21:03 UTCTickers: $ALDX Read the full article at SEC EDGAR